A vaccine administered during pregnancy is significantly cutting hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials confirming a decrease of more than 80 per cent. The jab, offered to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by enhancing maternal immunity and transferring immunity through the placenta. A major new study examining nearly 300,000 births across England between September 2024 and March 2025 has demonstrated the vaccine’s “excellent protection” during the timeframe when infants are most vulnerable to the virus. RSV affects roughly 50 per cent of newborns and remains one of the primary reasons of hospital admission in babies under one year old, with more than 20,000 serious cases recorded annually across the UK.
How the immunisation protects vulnerable infants
RSV, or respiratory syncytial virus, is a common respiratory infection that affects roughly half of all newborns in their first few months of life. The virus can vary from causing mild cold-like symptoms to causing severe chest infections that cause babies to struggle to breathe and feed. In the most serious cases, the lung inflammation becomes life-threatening, with small numbers of infants dying from the infection each year. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the deeply distressing nature of severe RSV infections: “In babies with bad infections you can see their chest and lungs struggling, as they attempt to draw enough oxygen in. This is extremely frightening as a parent, frightening for good reason.”
The pregnancy vaccine works by stimulating the mother’s body’s defences to generate protective antibodies, which are then passed to the developing baby through the placenta. This maternal immunity provides newborns with immediate protection from the point of delivery, exactly when they are highly susceptible to RSV. The new study demonstrates that protection reaches approximately 85% when the vaccine is administered four weeks or more before delivery. Even shorter intervals between vaccination and birth can still provide meaningful protection, with evidence indicating that a two-week gap is sufficient to shield babies born slightly early. Dr Watson recommends pregnant women to have the vaccine on schedule, whilst noting that protection can still occur even if administered later in the third trimester.
- Nearly 85 per cent coverage when immunised four weeks before birth
- Antibodies from the mother passed through placenta protect newborns from day one
- Protection achievable with two-week gap before early delivery
- Vaccination in third trimester still provides meaningful infant protection
Compelling evidence from the latest research
The effectiveness of the pregnancy RSV vaccine has been demonstrated through a extensive research programme conducted across England, examining data from close to 300,000 babies born between September 2024 and March 2025. This constitutes approximately 90 per cent of all births during that half-year window, providing comprehensive and reliable information of the vaccine’s practical effectiveness. The study’s findings have been supported by the UK Health Security Agency as showing “excellent protection” for newborns during their earliest and most vulnerable period. The scope of this study provides healthcare professionals and expectant parents with assurance in the vaccine’s demonstrated effectiveness across different groups and contexts.
The results reveal a striking picture of the vaccine’s ability to protect. More than 4,500 babies were hospitalised with RSV during the study period, with the vast majority being infants whose mothers had not been given the vaccination. This stark contrast highlights the vaccine’s vital importance in preventing serious illness in newborns. The drop in hospital admissions surpassing 80 per cent represents a major public health success, possibly preventing thousands of infants from experiencing the distressing and potentially serious symptoms connected with severe RSV infection. These findings strengthen the importance of the vaccination programme established in the UK in 2024.
Research approach and coverage
The research examined birth and hospitalisation records from England over a six-month timeframe, capturing data on approximately 90% of all births during this timeframe. By examining nearly 300,000 babies born to vaccinated and unvaccinated mothers, researchers were able to establish direct comparisons of RSV infection rates and hospital admissions. The substantial sample size and thorough nature of the data gathering ensured that findings were statistically robust and reflective of the wider population, rather than individual cases or small subgroups.
The study specifically recorded hospital admissions for RSV among infants born to mothers who had been given the vaccine at different timepoints before delivery. This allowed researchers to establish the minimum time required between vaccination and birth for optimal protection, as well as to determine whether protection stayed significant with reduced timeperiods. The methodology assessed actual clinical results rather than laboratory-based settings, providing tangible evidence of how the vaccine works when delivered across diverse clinical settings and patient circumstances throughout the final three months of pregnancy.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Understanding RSV and its hazards
Respiratory syncytial virus, commonly referred to as RSV, is among the primary causes of hospitalisation in infants under one year of age across the United Kingdom. The virus affects approximately half of all newborns during their early months of life, with severity changing substantially from mild cold-like symptoms to severe, life-threatening chest infections. Over 20,000 infants require serious hospital treatment for RSV annually in the UK alone, placing considerable pressure on paediatric wards and neonatal units during busier periods.
The infection triggers inflammation deep within the lungs and airways, making it perilously hard for infected babies to feed and breathe adequately. Parents frequently observe their babies struggling visibly, their chests rising whilst they attempt to draw enough air into their compromised lungs. Whilst most newborns recover with clinical support, a limited though important number die from respiratory syncytial virus complications yearly, making vaccination as prevention a vital health service objective for safeguarding the youngest and most vulnerable individuals in the population.
- RSV produces inflammation in lungs, resulting in severe breathing difficulties in infants
- Half of all newborns catch the infection during their first few months alive
- Symptoms span from mild colds to serious chest infections that threaten life requiring hospitalisation
- More than 20,000 UK infants require serious hospital care for RSV each year
- Few infants die from RSV related complications each year in the UK
Uptake rates and expert recommendations
Since the RSV vaccine programme began in 2024, health officials have emphasised the significance of pregnant women receiving their jab at the optimal time for peak protection. Dr Conall Watson, lead for the national programme for RSV at the UK Health Security Agency, has stressed that timing matters greatly for ensuring newborns receive the strongest possible immunity from birth. Whilst the study demonstrates that vaccination performed at least four weeks prior to delivery offers approximately 85% protection, experts advise women to get their vaccine as early as possible from 28 weeks of pregnancy forward to enhance the antibodies passed to their babies through the placenta.
The messaging from public health bodies stays clear: pregnant women should make a priority of getting vaccinated during their third trimester, even if circumstances mean they cannot receive the jab at the ideal window. Dr Watson has reassured expectant mothers that protection remains still achievable with shorter intervals between vaccination and birth, including even a fourteen-day window for those giving birth ahead of schedule. This flexible approach acknowledges the realities of pregnancy and childbirth whilst ensuring strong protection for vulnerable newborns during their most critical early months when RSV poses the greatest risk of serious illness.
Regional disparities in immunisation
Whilst the RSV vaccine programme has been rolled out across England, uptake rates and implementation timelines have varied across different regions and NHS trusts. Some areas have attained greater immunisation rates among eligible pregnant women, whilst others remain focused to boost understanding and access to the jab. These geographical variations reflect variations in healthcare infrastructure, engagement approaches, and community involvement initiatives, though the national data demonstrates robust and reliable protection irrespective of geographical location.
- NHS trusts deploying varied communication campaigns to connect with pregnant women
- Geographic variations in vaccine uptake rates in different parts of England necessitate strategic intervention
- Community health services adapting programmes to suit community needs and circumstances
Real-world impact and parental perspectives
The vaccine’s outstanding effectiveness translates into tangible benefits for families across the United Kingdom. With more than 20,000 babies hospitalised annually due to RSV before the introduction of this protective measure, the 80% decrease in admissions represents thousands of infants spared from serious illness. Parents no more face the troubling prospect of seeing their babies gasping for air or labour to feed, symptoms that define critical RSV illness. The vaccine has markedly changed the picture of neonatal breathing health, providing expectant mothers a proactive tool to shield their most at-risk babies during those critical early months.
For families like that of Malachi, whose serious RSV infection resulted in severe brain damage, the vaccine’s accessibility carries profound emotional significance. His mother’s support of the jab emphasises the life-altering consequences that vaccine-preventable disease can cause to young children and their families. Whilst Malachi’s experience precedes the vaccine programme, his story resonates strongly with parents now provided with protection. The knowledge that such grave complications—hospital stay, oxygen dependency, neurological damage—are now largely preventable has given considerable reassurance to women in pregnancy navigating their third trimester, transforming what was once an inevitable seasonal threat into a manageable health risk.